scholarly journals Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy

2011 ◽  
Vol 22 (7) ◽  
pp. 1507-1519 ◽  
Author(s):  
E. Felip ◽  
C. Gridelli ◽  
P. Baas ◽  
R. Rosell ◽  
R. Stahel
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
First Line ◽  
Molecular Tests ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

Third-line therapy and beyond for patients with advanced/metastatic non-small cell lung cancer (NSCLC).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e19160-e19160
Author(s):  
Jesus Corral Jaime ◽  
Miriam Gonzalez de la Peña ◽  
Miriam Alonso ◽  
Amparo Sanchez Gastaldo ◽  
Maria Dolores Mediano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Metastatic Nsclc ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

e19160 Background: Lung cancer is the leading cause of cancer-related deaths globally, with a 15% 5-year survival rate. Platinum-based chemotherapy constitutes the main treatment modality, with a median overall survival (OS) of approximately 10–12 months. The current National Comprehensive Cancer Network (NCCN) guidelines recommend several options for first-line and second-line therapies but endorse only erlotinib/gefitinib as third-line therapy in unselected patients, as well as crizotinib in ALK-positive selected patients.The paucity of approved agents for third-line therapy and beyond for patients with non-small cell lung cancer (NSCLC) constitutes an important unmet medical need. Methods: Retrospective analysis of 22 patients with advanced/metastatic NSCLC in progression after a minimum of 3 lines of therapy. Results: Between January 2009 and October 2012, 22 patients were analysed. Median age at diagnosis was 62 years old. 15% of patients were never smokers and 72.7% had non squamous NSCLC histology. Stage at diagnosis resulted: 6 (27.3%) stage IIIA, 3 (13.6%) stage IIIB and 13 (59.1%) stage IV. 3 (13.6%) patients were EGFR mutation carriers and 1(1%) patient had ALK translocation. Third line therapy options resulted a clinical trial (27.3%), erlotinib (22.7%), paclitaxel/gemcitabine (13.6%), docetaxel (9.1%) and crizotinib (4.5%). Estimated median progression-free survival (PFS) between first and second line therapy was 5.3 months; PFS between second and third line resulted 4.4 months. Median PFS and overall survival (OS) beyond third line treatment has not been reached yet. Conclusions: Currently, erlotinib/gefitinib and crizotinib, which target EGFR and ALK, are the only recommended agents for third-line therapy in patients with advanced/metastatic NSCLC. Real-world clinical practice reveals a variety of chemotherapeutic agents used in this setting. Additional systemic and/or targeted therapeutic under development, with complementary biomarker analysis, should be the key in identifying those patients most likely to benefit from newer agents.

scholarly journals Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer

2012 ◽  
Vol 7 (10) ◽  
pp. 1594-1601 ◽  
Author(s):  
Vassiliki A. Papadimitrakopoulou ◽  
Jean-Charles Soria ◽  
Annette Jappe ◽  
Valentine Jehl ◽  
Judith Klimovsky ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

scholarly journals P3.02b-065 Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer

2017 ◽  
Vol 12 (1) ◽  
pp. S1229-S1230
Author(s):  
Nikhil Pande ◽  
Amit Joshi ◽  
Vanita Noronha ◽  
Vijay Patil ◽  
Anuradha Chougule ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?

Lung Cancer ◽  
2010 ◽  
Vol 68 (3) ◽  
pp. 433-437 ◽  
Author(s):  
Mario Scartozzi ◽  
Paola Mazzanti ◽  
Riccardo Giampieri ◽  
Rossana Berardi ◽  
Eva Galizia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Predictive Factors ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line ◽  
Nsclc Patients

scholarly journals Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting

2019 ◽  
Vol 15 (30) ◽  
pp. 3491-3502 ◽  
Author(s):  
Jason C Simeone ◽  
Beth L Nordstrom ◽  
Ketan Patel ◽  
Alyssa B Klein
Keyword(s):  
Lung Cancer ◽  
Treatment Patterns ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
First Line ◽  
Metastatic Nsclc ◽  
First Line Therapy ◽  
Line Therapy ◽  
Third Line

Aim: To conduct a retrospective analysis of electronic medical record data to understand real-world treatment patterns and overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC). Materials & methods: We included n = 9656 adults (≥18 years) with metastatic NSCLC and no prior therapy. Data from 1 January 2013 to 31 January 2017 were analyzed. Results: Carboplatin plus paclitaxel was the most common first-line therapy (18.6%), and nivolumab was the most common second- (31.0%) and third-line (38.4%) therapy; 26.7% of all patients were untreated. Median OS from initial metastatic diagnosis was 11.1 months (95% CI: 10.8–11.5). Second-line immunotherapy extended OS by over 3 months versus second-line chemotherapy. Conclusion: Platinum-based therapy was the most common first-line therapy, and immunotherapy was the most common second- and third-line therapy. Median OS of patients with metastatic NSCLC was <1 year.

Sign in / Sign up

Export Citation Format

Share Document